PMID- 12860078 OWN - NLM STAT- MEDLINE DCOM- 20031118 LR - 20220316 IS - 0378-1135 (Print) IS - 0378-1135 (Linking) VI - 95 IP - 1-2 DP - 2003 Aug 29 TI - Interleukin 6, serum amyloid A and haptoglobin as markers of treatment efficacy in pigs experimentally infected with Actinobacillus pleuropneumoniae. PG - 75-89 AB - The possibility to use acute phase proteins to monitor the elimination of a bacterial infection in pigs would facilitate an objective assessment of treatment with various antimicrobial substances. To examine this possibility, the acute phase response (IL-6, serum amyloid A (SAA), and haptoglobin) elicited by Actinobacillus pleuropneumoniae and its reduction on treatment with various antibiotics was studied in serum from specific pathogen free (SPF) pigs. Pigs were infected intranasally with A. pleuropneumoniae serotype 2, and either left as non-treated control pigs or treated with different antibiotics intramuscularly at onset of respiratory disease (20h post-infection). Pigs responded to the infection with prominent increases in activity and concentrations of IL-6, SAA, and haptoglobin. These responses were to a certain extent overlapping and covered the time span from a few hours after infection until development of detectable levels of specific antibodies (7-10 days post-infection in untreated pigs). The haptoglobin response lasted until the end of the study on day 17 and thereby partly coincided with the antibody response. Treatment with antimicrobials that effectively reduced establishment of the infection with A. pleuropneumoniae also reduced the duration of all three acute phase responses, and reduced the concentration of serum haptoglobin. In contrast, less efficacious treatments did not reduce these acute phase responses. Thus, acute phase reactants can be applied to monitor therapeutic effects of antimicrobial drugs in the pig and measurements of IL-6, SAA and haptoglobin could add valuable information about the stage of infection during a disease outbreak. FAU - Hulten, C AU - Hulten C AD - Department of Clinical Chemistry, P.O. Box 7038, Uppsala, Sweden. FAU - Johansson, E AU - Johansson E FAU - Fossum, C AU - Fossum C FAU - Wallgren, P AU - Wallgren P LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - Netherlands TA - Vet Microbiol JT - Veterinary microbiology JID - 7705469 RN - 0 (Anti-Bacterial Agents) RN - 0 (Antibodies, Bacterial) RN - 0 (Apolipoproteins) RN - 0 (Haptoglobins) RN - 0 (Interleukin-6) RN - 0 (Serum Amyloid A Protein) SB - IM MH - Actinobacillus Infections/blood/drug therapy/microbiology/*veterinary MH - Actinobacillus pleuropneumoniae/*growth & development MH - Acute-Phase Reaction/blood/drug therapy/microbiology/veterinary MH - Animals MH - Anti-Bacterial Agents/*pharmacology/therapeutic use MH - Antibodies, Bacterial/blood MH - Apolipoproteins/*blood MH - Female MH - Haptoglobins/*metabolism MH - Interleukin-6/*blood MH - Lung/microbiology/pathology MH - Male MH - Pleuropneumonia/blood/drug therapy/microbiology/*veterinary MH - Serum Amyloid A Protein MH - Specific Pathogen-Free Organisms MH - Swine MH - Swine Diseases/*blood/drug therapy/microbiology EDAT- 2003/07/16 05:00 MHDA- 2003/12/03 05:00 CRDT- 2003/07/16 05:00 PHST- 2003/07/16 05:00 [pubmed] PHST- 2003/12/03 05:00 [medline] PHST- 2003/07/16 05:00 [entrez] AID - S0378113503001366 [pii] AID - 10.1016/s0378-1135(03)00136-6 [doi] PST - ppublish SO - Vet Microbiol. 2003 Aug 29;95(1-2):75-89. doi: 10.1016/s0378-1135(03)00136-6.